Antidepressants and sexual dysfunction: Epidemiology, mechanisms and management;Antidepressivi e disfunzione sessuale: Epidemiologia, meccanismi e strategie di trattamento

Italian Journal of Psychopathology

Volumn 16, Issue 1, 2010, Pages 104-113

  Chiesa, A ^a   Serretti, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressants; Arousal; Desire; Management; Orgasm; Sexual dysfunction

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMINEPTINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DULOXETINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PHENELZINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADVERSE OUTCOME; ARTICLE; COCHRANE LIBRARY; ERECTILE DYSFUNCTION; HUMAN; MAJOR DEPRESSION; ORGASM; PATIENT COMPLIANCE; PHYSICIAN; PRESCRIPTION; RATING SCALE; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; STRUCTURED QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT;

EID: 77952994825     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. World Health Organization. Impact of disorders. http://www.who.int/whr/ 2001/chapter2/en/index3.html 2001.
2. Segraves RT, Balon R. Sexual pharmacology: fast facts. New York: WW Norton 2003.
3. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67-85.
4. Rothschild AJ. Sexual side effects of antidepressants. J Clin Psychiatry 2000;61:28-36.
5. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychopharmacol 2006;67:33-37
6. Mathew R, Weinman M. Sexual dysfunctions in depression. Arch Sex Behav 1982;11:323-328
7. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55:580-592
8. Roose SP. Depression: links with ischemic heart disease and erectile dysfunction. J Clin Psychiatry 2003;64(Suppl 10):26-30. (Pubitemid 37128665)
9. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3):10-21.
10. Montejo AL, Garcia M, Espada M, Rico-Villademoros F, Llorca G, Izquierdo JA. Psychometric characteristics of the psychotropic-related sexual dysfunction questionnaire. Spanish work group for the study of psychotropic-related sexual dysfunctions. Actas Esp Psiquiatr 2000;28:141-150
11. Hirschfeld RM. Care of the sexually active depressed patient. J Clin Psychiatry 1999;60(Suppl 17):32-35
12. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53;119-122
13. Balon R, Yeragani VK, Pohl R, Ramesh C. Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 1993;54:209-212
14. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995;25:191-201.
15. Shen WW, Hsu JH. Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Int J Psychiatry Med 1995;25:239-248
16. Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT. Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial. Br J Psychiatry 1987;151:107-112
17. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259-266
18. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40.
19. Clayton A, McGarvey EL, Clavet GJ. The changes in sexual functioning questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 1997;33:731-745
20. Zajecka J, Mitchell S, Fawcett J. Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull 1997;33:755-760
21. Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. Austr N Z J Psychiatry. 2009;43:795-808.
22. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006;91:27-32.
23. Dannon PN, Iancu I, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, et al. A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder. Clin Neuropharmacol 2007;30:326-334
24. th edn. Washington, DC: American Psychiatric Association 1994.
25. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006;26:579-86.
26. Zajecka J. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychopharmacol 2001;62(Suppl 3):35-43.
27. Saks B, Gillespie M. Psychotropic medication and sexual function in women: an update. Arch Womens Ment Health 2002;4:139-144
28. Segraves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989;46:275-284
29. Bitran D, Hull EM, Holmes GM, Lookingland KJ. Regulation of male rat copulatory behavior by preoptic incertohypothalamic dopamine neurons. Brain Res Bull 1988;20:323-331
30. Baldessarini RJ, Marsh E. Fluoxetine and side effects. Arch Gen Psychiatry 1990;47:191-192
31. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979;45:165-175
32. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med 1992;22:305-327
33. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32:653-658
34. Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychopharmacol 1991;52:66-68
35. Crenshaw TL, Goldberg JP. Sexual pharmacology: drugs that affect sexual functioning. New York: WW Norton and Co. 1996.
36. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM., Fibiger HC, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychopharmacol 1995;56:395-401.
37. Philipp M, Kohnen R, Benkert O. A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 1993;7:149-153
38. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, McMahon FJ. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharm 2009;34:1819-1828
39. Zourkova A, Hadasova E. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment. 2002. J Sex Marital Ther 2002;28:451-461
40. Zourkova A, Ceskova E, Hadasova E, Ravcukova B. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther 2007;33:343-355
41. Taylor D, Paten C, Kerwin R. The Maudsley prescribing guidelines, 10th edition. Andover, UK: Thompson Publishing Services 2009.
42. Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord 2002;88: 241-254
43. Bellantuono C, Balestrieri M. Antidepressivi e disfunzione sessuale. In: Trattato di psicofarmacologia clinica. Roma: Il Pensiero Scientifico Editore 2003.
44. Landen M, Hogberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with Citalopram or paroxetine. J Clin Psychopharmacol 2005;66:100-106
45. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007;4:917-929
46. Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychopharmacol 2006;67:736-746
47. Ashton AK, Hamer R, Rosen RC. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment. A large-scale retrospective study of 596 psychiatric outpatients. J Sex Mar Ther 1997;23:165-175
48. Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23:1040-1058
49. Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, van der Hoop RG, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004;24:118-125
50. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry 2004;4:16.
51. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-470
52. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychopharmacol 2000;61:276-281
53. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-399
54. Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry 2001;47:174-180
55. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21:643-658
56. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychopharmacol 1997;58:532-537
57. Segraves RT, Kavoussi R, Hughes AR, Batey SR, Johnston JA, Donahue R, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2002;20122-20128
58. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001;158:899-905.
59. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-333
60. Harrison WM, Stewart J, Ehrhardt AA, Rabkin J, McGrath P, Liebowitz M, et al. A controlled study of the effects of antidepressants on sexual function. Psychopharmacol Bull 1985;21:85-88
61. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208-214
62. Kennedy S. Favorable sexual profile of agomelatine in depressed patients. European Neuropsychopharmacology 2006;16:S319.
63. Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RM, Houser TL, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11:205-215